种子扩增试验诊断多系统萎缩的敏感性与特异性:一项多中心队列研究
这项多中心队列研究使用新型α-突触核蛋白种子扩增试验(synSAA)检测脑脊液和脑组织样本,发现该试验可产生两种荧光扩增模式:1型对应路易小体,2型对应胶质细胞包涵体。在富集多系统萎缩的队列中,该试验对多系统萎缩的敏感性为87%(95%CI 80-93),对2型种子的特异性为77%(67-85)。作者认为该试验可能有助于突触核蛋白病的早期诊断,但需要额外的正式验证工作。
要点
- 新型synSAA可区分路易小体与胶质细胞包涵体来源的α-突触核蛋白种子。
- 合并富集多系统萎缩队列中,对多系统萎缩敏感性87%,2型种子特异性77%。
- 真实生活队列中敏感性91%,但2型种子特异性降至68%。
核心结论
- 新型synSAA产生的扩增模式能够识别潜在的α-突触核蛋白病理,显示两种荧光水平对应突触核蛋白病的不同病理标志。
- 该synSAA可能有助于临床试验中突触核蛋白病的早期诊断,并可能用于临床,但需要额外的正式验证工作。
研究设计与样本
- 多中心队列研究,使用新型synSAA通过荧光扩增和检测种子,分析设盲的脑脊液和脑样本。
- 样本来自四个国家七个医疗中心的八个可用队列:纽约脑库(NYBB)、宾夕法尼亚大学(UPENN)、Paracelsus-Elena-Klinik(DeNoPa和KAMSA)、巴塞罗那医院诊所(BARMSA)、图宾根大学(EKUT)、哥德堡大学(UGOT)和卡罗林斯卡学院(KIMSA)。
- 参与者包括临床诊断或病理确认的多系统萎缩、帕金森病、路易体痴呆、孤立性快速眼动睡眠行为障碍(IRBD)、非突触核蛋白病以及健康对照。
- 临床队列按预期诊断准确性分为研究队列(纵向随访)和真实生活队列(单次访视)。
- 敏感性和特异性分别根据病理诊断(金标准)和临床诊断(参考标准)进行估计。
主要发现
- 在23份脑样本(来自NYBB队列)中,含路易小体的样本synSAA阳性并产生高荧光扩增模式(定义为1型);含胶质细胞包涵体的样本synSAA阳性并产生中等荧光(定义为2型);无α-突触核蛋白病理的样本荧光低于阈值且synSAA阴性。
- 在21份病理确认的脑脊液样本(来自UPENN队列)中,含路易小体的样本为synSAA阳性1型;含胶质细胞包涵体的样本为synSAA阳性2型;含四重复tau蛋白病的样本为synSAA阴性。
- 在DeNoPa研究队列(无多系统萎缩样本)中,新型synSAA对80例帕金森病参与者的敏感性为95%(95%CI 88-99),对21例IRBD参与者的敏感性为95%(76-100),对60例健康对照的特异性为95%(86-99)。
- 合并BARMSA、EKUT、KAMSA、UGOT和KIMSA等富集多系统萎缩病例的队列,新型synSAA对多系统萎缩的敏感性为87%(95%CI 80-93),对2型种子的特异性为77%(67-85)。
- 仅研究队列(BARMSA和EKUT)中的多系统萎缩参与者,新型synSAA敏感性为84%(95%CI 71-92),对2型种子的特异性为87%(74-95);而真实生活队列(KAMSA、KIMSA和UGOT)中的病例敏感性为91%(95%CI 80-97),但2型种子特异性降低至68%(53-81)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pathological hallmarks of multiple system atrophy and Parkinson's disease are, respectively, misfolded-α-synuclein-laden glial cytoplasmic inclusions and Lewy bodies. CSF-soluble misfolded α-synuclein aggregates (seeds) are readily detected in people with Parkinson's disease by α-synuclein seed amplification assay (synSAA), but identification of seeds associated with multiple system atrophy for diagnostic purposes has proven elusive. We aimed to assess whether a novel synSAA could reliably distinguish seeds from Lewy bodies and glial cytoplasmic inclusions. METHODS: In this multicentre cohort study, a novel synSAA that multiplies and detects seeds by fluorescence was used to analyse masked CSF and brain samples from participants with either clinically diagnosed or pathology-confirmed multiple system atrophy, Parkinson's disease, dementia with Lewy bodies, isolated rapid eye movement sleep behaviour disorder (IRBD), disorders that were not synucleinopathies, or healthy controls. Participants were from eight available cohorts from seven medical centres in four countries: New York Brain Bank, New York, USA (NYBB); University of Pennsylvania, Philadelphia, PA, USA (UPENN); Paracelsus-Elena-Klinik, Kassel, Germany (DeNoPa and KAMSA); Hospital Clinic Barcelona, Spain (BARMSA); Universität Tübingen, Tübingen, Germany (EKUT); Göteborgs Universitet, Göteborgs, Sweden (UGOT); and Karolinska Institutet, Stockholm, Sweden (KIMSA). Clinical cohorts were classified for expected diagnostic accuracy as either research (longitudinal follow-up visits) or real-life (single visit). Sensitivity and specificity were estimated according to pathological (gold standard) and clinical (reference standard) diagnoses. FINDINGS: In 23 brain samples (from the NYBB cohort), those containing Lewy bodies were synSAA-positive and produced high fluorescence amplification patterns (defined as type 1); those containing glial cytoplasmic inclusions were synSAA-positive and produced intermediate fluorescence (defined as type 2); and those without α-synuclein pathology produced below-threshold fluorescence and were synSAA-negative. In 21 pathology-confirmed CSF samples (from the UPENN cohort), those with Lewy bodies were synSAA-positive type 1; those with glial cytoplasmic inclusions were synSAA-positive type 2; and those with four-repeat tauopathy were synSAA-negative. In the DeNoPa research cohort (which had no samples from people with multiple system atrophy), the novel synSAA had sensitivities of 95% (95% CI 88-99) for 80 participants with Parkinson's disease and 95% (76-100) for 21 participants with IRBD, and a specificity of 95% (86-99) for 60 healthy controls. Overall (combining BARMSA, EKUT, KAMSA, UGOT, and KIMSA cohorts that were enriched for cases of multiple system atrophy), the novel synSAA had 87% sensitivity for multiple system atrophy (95% CI 80-93) and specificity for type 2 seeds was 77% (67-85). For participants with multiple system atrophy just in research cohorts (BARMSA and EKUT), the novel synSAA had a sensitivity of 84% (95% CI 71-92) and a specificity for type 2 seeds of 87% (74-95), whereas cases from real-life cohorts (KAMSA, KIMSA, and UGOT) had a sensitivity of 91% (95% CI 80-97) but a decreased specificity for type 2 seeds of 68% (53-81). INTERPRETATION: The novel synSAA produced amplification patterns that enabled the identification of underlying α-synuclein pathology, showing two levels of fluorescence that corresponded with different pathological hallmarks of synucleinopathy. The synSAA might be useful for early diagnosis of synucleinopathies in clinical trials, and potentially for clinical use, but additional formal validation work is needed. FUNDING: Michael J Fox Foundation for Parkinson's Research, Amprion.
引用
- Ma Y, Farris CM, Weber S, et al. Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. Lancet Neurol. 2024. PMID: 39577923. doi:10.1016/S1474-4422(24)00395-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。